Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Beta thalassaemia

- PMLiVE

Vertex reveals promising data from first CRISPR-treated patients

Investigational gene therapy has potentially curative effect

- PMLiVE

FDA lifts hold on Vertex and CRISPR Therapeutics sickle cell therapy

Trial could begin by year end

- PMLiVE

Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

The candidate is expected to start a phase II trial in the coming months

- PMLiVE

India denies Vertex patent on cystic fibrosis drug Orkambi

Says treatment is neither innovative or more effective than its predecessor

- PMLiVE

Marc Becker joins CRISPR Therapeutics

He becomes chief financial officer

- PMLiVE

Vertex submits Kalydeco combo for cystic fibrosis

Seeks approval in both US and Europe

- PMLiVE

Vertex will file combination cystic fibrosis therapy this year

Data supports use of lumacaftor alongside Kalydeco

Biogen Idec building

Biogen Idec taps Sangamo for blood disorder drugs

Deal is worth up to $320m

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links